Clinical Trials
At the Stony Brook Heart Institute, our physician-scientists are dedicated to advancing heart care through innovative research. We participate in carefully chosen national and international clinical trials, exploring new ways to prevent, diagnose and treat heart disease. This commitment to research is a core part of our mission to provide exceptional patient care.
Participating in a clinical trial may give you access to promising new treatments before they become widely available. Throughout the process, you’ll be supported by a team of expert cardiac specialists who will monitor your health and progress closely. All trials are carefully scrutinized for patient safety by our specialists and the institution's trial review board.
Participation is completely voluntary and will never affect the quality or standards of your regular care. Before joining a trial, you’ll receive a full explanation of your options from your cardiologist or surgeon, ensuring you can make an informed decision.
To learn more about how clinical trials work and whether joining one is right for you, talk with your cardiologist or give us a call.
- VEST/PREDICTS: A study to see if an external automatic defibrillator vest will reduce overall mortality in the first 60 days following an MI in patients with EF < 35%.
Principal investigator: Eric J. Rashba, MD - Protego: To determine the long-term safety and reliability of BIOTRONIK’s ProtegoDF4 lead, as used in conjunction with a BIOTRONIK DF4 compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) pulse generator.
Principal investigator: Eric J. Rashba, MD - Cabana: To determine if catheter ablation is superior to antithrombotic medication in eliminating atrial fibrillation. NIH STUDY.
Principal investigator: Eric J. Rashba, MD - Tacticath: To evaluate the safety and effectiveness of the TactiCath Quartz Percutaneous Ablation Catheter in the treatment of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated radiofrequency ablation.
Principal investigator: Roger Fan, MD - SICD-PAS: To determine long term safety and effectiveness outcomes associated with the implantation of the SQ-RX pulse generator and Q-TRAK electrode in a commercial clinical setting.
Principal investigator: Eric J. Rashba, MD - Adapt Response: The purpose of this study is to test the hypothesis that market released CRT devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).
Principal investigator: Eric J. Rashba, MD - LSS: To evaluate, document and report on the appropriate clinical performance, the long-term reliability and the functional integrity of the 4-SITE Lead/Header System.
Principal investigator: Eric J. Rashba, MD - Quadripolar: To evaluate the acute and chronic performance of a Quadripolar CRT-D device system in patients indicated for cardiac resynchronization therapy.
Principal investigator: Eric J. Rashba, MD - Navigate: To determine the safety, performance and effectiveness of the ACUITY™ X4 quadripolar coronary venous leads and the RELIANCE 4-FRONT™ ventricular defibrillation leads to satisfy FDA requirements for premarket submission. Additionally, data from this study will be used to support post-market approval requirements for the ACUITY X4 and RELIANCE 4-FRONT leads.
Principal investigator: Eric J. Rashba, MD - GLORIA-AF: To investigate the patient’s characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in non-valvular atrial fibrillation (AF) patients and to collect outcome events.
Principal investigator: Eric J. Rashba, MD
- Bariatric: To understand the effects of bariatric (weight loss) surgery on the electrical activity of the heart.
Principal investigator: Eric J. Rashba, MD - Cardiac surgery: To understand the effects of insulin resistance on the electrical activity of the heart.
Principal investigator: Eric J. Rashba, MD - Haptic Feedback: To collect physiologic data that will enable training physicians with an enhanced ability to appreciate catheter and cardiovascular tissue properties and palpate the effect of catheter contact on moving biological tissue.
Principal investigator: Eric J. Rashba, MD
- PROACTIVE-HF-2: A Prospective, Multi-Center, Open Label, Randomized, Control, Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class II - III Heart Failure Patients. The main purpose of this study is to investigate the safety and effectiveness of the study device in helping to reduce Heart Failure Hospitalizations.
Principal investigator: Hal Skopicki, MD, PhD - ASK-BIO: A phase 2, adaptive, double-blinded, placebo controlled, randomized, multi-center trial to evaluate the efficacy, safety and tolerability of intracoronary infusion of AB-1002 in adult subjects with New York Heart Association (NYHA) Class III heart failure and non-ischemic cardiomyopathy. The purpose of the clinical study ASK-CHF2-CS201 is to evaluate the safety and efficacy of AB-1002 for the treatment of patients with heart failure and non-ischemic cardiomyopathy.
Principal investigator: Hal Skopicki, MD, PhD - HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.
Principal investigator: Hal Skopicki, MD, PhD - REDEFINE: Randomized trial to determine the efficacy and safety of FINErenone on morbidity and mortality among heart failure patients with left ventricular ejection fraction greater than or equal to 40% hospitalized due to an episode of acute decompensated Heart Failure. This study will find out whether finerenone (which is the drug we will be investigating in this study) can lower the risk of heart failure and death in patients who are hospitalized with heart failure.
Principal investigator: Hal Skopicki, MD, PhD
